^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC)

Published date:
10/09/2014
Excerpt:
GnRH receptor expression of TNBC cell lines MDA-MB-231 and HCC1806 was investigated...Cells were treated with triptorelin, chemotherapeutic agents (cisplatin, docetaxel, AEZS-112), PI3K/AKT inhibitors (perifosine, AEZS-129), an ERK inhibitor (AEZS-134), and dual PI3K/ERK inhibitor AEZS-136 applied as single agent therapies and in combinations. MDA-MB-231 and HCC1806 TNBC cells both expressed receptors for GnRH...In HCC1806 cells, synergy occurred when triptorelin was applied with PI3K/AKT inhibitors perifosine and AEZS-129.
DOI:
10.1007/s11523-014-0340-y